title: Oral flecainide is effective in management of refractory tachycardia in infants.
abstract: BACKGROUND
  Propranolol and digoxin have been used as first line drugs for treatment of supraventricular tachycardia (SVT) in infants. Flecainide and other drugs have been effective as a second line treatment for controlling refractory SVT.
  
  
  METHODS
  This is a prospective study without randomization and control. The inclusion criteria were: infants (≤12 months) with tachyarrhythmia who failed to respond to first line drugs. Patients having post-surgical arrhythmias were excluded from the study.
  
  
  RESULTS
  A total of 8 infants were treated with flecainide for refractory tachyarrhythmia's. Diagnosis on electrocardiogram (ECG) was atrioventricular reentry tachycardia (AVRT) in 5, atrial ectopic tachycardia (AET) in 2, a combination of AVRT and atrioventricular nodal reentry tachycardia (AVNRT) in 1. All patients had failed trial of antiarrhythmic drugs prior to presentation: digoxin and propranolol in 7, amiodarone in 3, cardioversion in 1. Flecainide (80-130 mg/m(2) orally) resulted in termination of the tachycardia in all 8 patients. Acute pharmacological termination of arrhythmia occurred with oral flecainide loading in 1 and temporarily with intravenous esmolol loading in 1 patient. Adjuvant therapy in form of propranolol was used in 5 and digoxin in 2. There were no side effects noted. Four episodes of recurrence were noted in 3 patients over 2 years, all of which responded to dose increase. Mean follow up time is 24.75 months.
  
  
  CONCLUSIONS
  This small case series indicates that flecainide is an effective antiarrhythmic agent, free of side effects and when used orally is capable of terminating and controlling relatively resistant supraventricular tachycardia in children.
authors: Pediatric Cardiology & Congenital Cardiac Surgery, Indraprastha Apollo Hospital, New Delhi, India. Electronic address: vkohli_md@yahoo.com.
authors: Vikas
authors: V
authors: Kohli
mesh_terms: D000284:Administration, Oral; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D005424:Flecainide / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D011446:Prospective Studies; D013611:Tachycardia, Atrioventricular Nodal Reentry / Q000188:drug therapy*; D013612:Tachycardia, Ectopic Atrial / Q000188:drug therapy*; D017211:Treatment Failure
chemical_list: D000889:Anti-Arrhythmia Agents; D005424:Flecainide
references: Am J Cardiol. 1988 Aug 25;62(6):16D-22D
references: 3136630
references: J Pediatr. 1981 Jun;98(6):875-82
references: 7229788
references: Am J Cardiol. 2003 Nov 1;92(9):1045-9
references: 14583354
references: Am Heart J. 1992 Dec;124(6):1614-21
references: 1462922
references: J Cardiovasc Med (Hagerstown). 2009 May;10(5):372-5
references: 19300276
references: N Engl J Med. 1989 Aug 10;321(6):406-12
references: 2473403
references: J Am Coll Cardiol. 1995 Apr;25(5):1195-8
references: 7897134
references: Circulation. 2005 Nov 29;112(22):3470-7
references: 16316969
references: Eur J Pediatr. 2003 Dec;162(12):880-4
references: 14508682
references: Europace. 2008 May;10(5):629-35
references: 18385122
references: Pediatr Cardiol. 2006 Mar-Apr;27(2):199-203
references: 16391988
references: J Am Coll Cardiol. 2002 Feb 6;39(3):517-20
references: 11823091